<DOC>
	<DOCNO>NCT02561793</DOCNO>
	<brief_summary>440 woman expect poor ovarian response undergo IVF/ICSI ( intracytoplasmic sperm injection ) randomly divide 2 group use computer generate random number . Group 1 ( study group ) receive Dehydroepiandrosterone ( DHEA ) 25 mg ( DHEA 25mg , Natrol , USA ) t.d.s daily 12 week start IVF/ICSI cycle . Group 2 ( control group ) receive placebo . Patients include study subject full history take clinical examination . On second day menstruation serum FSH , LH , Prolactin Oestradiol assess antral follicular count ( AFC ) assess use vaginal ultrasound scan . AFC define number follicle measure 3-10mm . All patient gonadotropin antagonist protocol Human menopausal gonadotrophin ( HMG ) stimulation day ( Human chorionic gonadotrophin ( HCG ) administration . On day HCG administration , ovarian ultrasound scan perform use transvaginal probe . Oocytes aspirate 34-36 hour HCG administration . Oocytes fertilized embryo transfer . Both group compare regard proportion pregnancy .</brief_summary>
	<brief_title>DHEA Versus Placebo Women With Poor Ovarian Response</brief_title>
	<detailed_description>The study conduct Cairo university hospital Dar Al-Teb Infertility Assisted conception center , Giza Egypt . All patient attend centre evaluate expected ovarian response.Patients fulfil Bologna criterion definition poor ovarian response invite participate study sign inform consent form . The invitation include clear full explanation study . 440 woman randomly divide 2 group use computer generate random number . Group 1 ( study group ) include 220 woman receive DHEA 25 mg t.d.s ( DHEA® , Natrol , USA ) twice daily 12 week start IVF/ICSI cycle . Group 2 include 220 woman receive oral placebo similar colour , size structure DHEA.. All woman fulfil inclusion criterion invite participate study . A write informed consent take woman sign consent include study . Patients include study subject full history take clinical examination include general , abdominal gynecological examination . This follow vaginal ultrasound scan ass uterus , ovary pelvic mass . On second day menstruation serum follicle stimulate hormone ( FSH ) , luteinizing hormone ( LH ) , Prolactin Oestradiol assess antral follicular count ( AFC ) assess use vaginal ultrasound scan . AFC define number follicle measure 3-10mm . The stimulation protocol start day 2 use 450-300 IU HMG ( Merional® IBSA , Lugano , Switzerland ) gonadotropin-releasing hormone antagonist , cetrorelix ( Cetrotide® Merck Serono , Darmstadt , Germany ) 0.025 mg daily . Gonadotropins administer 4 5 day , dose adjust accord ovarian response . The ovarian response monitor transvaginal ultrasound serum E2 level . When three follicle reach maximum diameter 16 mm , highly purify HCG 5000 10,000 IU ( Choriomon ®IBSA ) administer . The procedure cancel less 3 follicle 16 mm size present 12 day start gonadotropin despite dos reach 450 IU . The cycle also cancel risk ovarian hyperstimulation like massive ovarian enlargement serum estradiol exceed 3000pg/L Transvaginal oocyte retrieval perform 34-36 h administration HCG . Oocytes fertilized either via IVF ICSI base couple 's history . Fertilization assess 16-18 h IVF ICSI . Embryos transfer Day 3 5 . Vaginal tablet contain progesterone ( Prontogest® IBSA ) 400 mg/day give fertilization confirm . A pregnancy test do 2 week embryo transfer . For patient positive pregnancy test , progesterone continue additional 4 week . Clinical pregnancy define Visualization intrauterine gestational sac 5 week embryo transfer .</detailed_description>
	<mesh_term>Infertility</mesh_term>
	<mesh_term>Dehydroepiandrosterone</mesh_term>
	<criteria>Women undergo IVF/ICSI treatment expect poor ovarian response accord Bologna criterion Women BMI &gt; 35 Kg/m2 Women single ovary Known allergy DHEA Diabetic woman insulin insulin lower DHEA level might reduce effectiveness DHEA supplement</criteria>
	<gender>Female</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>43 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>